Psoriatic Arthritis

• FDA label_change · 2025-06-27
  FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)

  FDA approves a supplemental application for Ustekinumab (Stelara) by Janssen Biotech, resulting in updated labeling.

• FDA label_change · 2025-03-26
  FDA Approved: RINVOQ — Supplemental Application (AbbVie Inc.)

  FDA approved AbbVie’s supplemental application for Rinvoq (upadacitinib), resulting in a labeling update for the product.

• FDA label_change · 2019-12-26
  FDA Approved: OTREXUP — Supplemental Application (Antares Pharma, Inc.)

  FDA approved a supplemental application for OTREXUP (methotrexate) from Antares Pharma, Inc., leading to changes in the labeling for this su…

• FDA label_change · 2019-01-29
  FDA Approved: TREMFYA — Supplemental Application (Janssen Biotech, Inc.)

  FDA approved a supplemental application for TREMFYA (guselkumab) by Janssen Biotech, Inc., resulting in changes to the labeling.

• FDA label_change · 2016-01-08
  FDA Approved: SIMPONI ARIA — Supplemental Application (Janssen Biotech, Inc.)

  FDA approved a supplemental application for SIMPONI ARIA (golimumab) to update the product labeling.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA label_change · 2015-08-05
  FDA Approved: SIMPONI ARIA — Supplemental Application (Janssen Biotech, Inc.)

  FDA approved a supplemental application for Simponi Aria (golimumab) filed by Janssen Biotech, Inc., resulting in changes to the product lab…

• FDA label_change · 2015-04-27
  FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)

  FDA announces that Amgen's supplemental application for OTEZLA (apremilast) has been approved, updating the product labeling accordingly.